Introduction
Introduction Statistics Contact Development Disclaimer Help
SARS-CoV-2 antibodies in dogs and cats in a highly infected area of...
by:
Samar Afif Jarrah
Louise Bach Kmetiuk
Fabrizia Valleriani
Barbara Bonfini
Alessio Lorusso
Violetta Vasinioti
Nicola Decaro
Marco Tulio dos Santos
Kledir Anderson Hofstaetter Spohr
Annamaria Pratelli
Anna Serroni
Sara Capista
Valéria Regia Franco Sousa
Alexander Welker Biondo
Luciano Nakazato
Valéria Dutra
Thumbnail
Download
Web page
SARS-CoV-2 was a worldwide threat during the COVID-19
pandemic, and the state of Mato Grosso had the second
highest mortality rate in Brazil, with 427. 4
deaths/100,000 inhabitants. However, no large-scale study
among dogs and cats in such highly infected areas of
Brazil has so far been conducted. Accordingly, the
present study reports on a serosurvey among dogs and cats
in Cuiab , capital of Mato Grosso from November 2020 to
July 2021, where the human mortality rate was 605/100,000
at that time. Overall, 33/762 dogs (4.3%) and 4/182 cats
(2.2%) were found to be seropositive for SARS-CoV-2
through ELISA, and 3/762 dogs (0.4%) and 3/182 cats
(1.6%) were seropositive through the serum neutralization
test. Cats presented higher seroprevalence with higher
titers of neutralizing antibodies. Although N-protein
based ELISA may be a good screening test, cross-
reactivity with other canine coronaviruses may impair its
diagnostic use among dogs.
Date Published: 2024-05-18 10:20:12
Identifier: fvets-10-00182
Item Size: 16167197
Language: eng
Media Type: texts
# Topics
open access
open access journal
research report
brief report
Brazil
companion animals
pets
serosurvey
coronavirus
SARS-CoV-2
# Collections
journals_contributions
journals
# Uploaded by
@zaryathelaika
# Similar Items
View similar items
PHAROS
You are viewing proxied material from tilde.pink. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.